Enria DA, Mills JN, Bausch D, Shieh W, Peters CJ, 2011. Arenavirus infections. Guerrant RL, Walker DH, Weller PF, eds. Tropical Infectious Diseases: Principles, Pathogens, and Practice, 3rd ed. Philadelphia, PA: Churchill Livingstone, 449ā461.
Frame JD, Baldwin JM Jr, Gocke DJ, Troup JM, 1970. Lassa fever, a new virus disease of man from West Africa. I. Clinical description and pathological findings. Am J Trop Med Hyg 19: 670ā676.
Bausch DG, Rollin PE, Demby AH, Coulibaly M, Kanu J, Conteh AS, Wagoner KD, McMullan LK, Bowen MD, Peters CJ, Ksiazek TG, 2000. Diagnosis and clinical virology of Lassa fever as evaluated by enzyme-linked immunosorbent assay, indirect fluorescent-antibody test, and virus isolation. J Clin Microbiol 38: 2670ā2677.
Wulff H, Lange JV, 1975. Indirect immunofluorescence for the diagnosis of Lassa fever infection. Bull World Health Organ 52: 429ā436.
Van der Waals FW, Pomeroy KL, Goudsmit J, Asher DM, Gajdusek DC, 1986. Hemorrhagic fever virus infections in an isolated rainforest area of central Liberia. Limitations of the indirect immunofluorescence slide test for antibody screening in Africa. Trop Geogr Med 38: 209ā214.
Fabiyi A, 1976. Lassa fever (arenaviruses) as a public health problem. Bull Pan Am Health Organ 10: 335ā337.
McCormick JB, Webb PA, Krebs JW, Johnson KM, Smith ES, 1987. A prospective study of the epidemiology and ecology of Lassa fever. J Infect Dis 155: 437ā444.
Pinneo L, Pinneo R, 1971. Mystery virus from Lassa. Am J Nurs 71: 1352ā1355.
Carey DE, Kemp GE, White HA, Pinneo L, Addy RF, Fom AL, Stroh G, Casals J, Henderson BE, 1972. Lassa fever. Epidemiological aspects of the 1970 epidemic, Jos, Nigeria. Trans R Soc Trop Med Hyg 66: 402ā408.
Frame JD, 1975. Surveillance of Lassa fever in missionaries stationed in West Africa. Bull World Health Organ 52: 593ā598.
Troup JM, White HA, Fom AL, Carey DE, 1970. An outbreak of Lassa fever on the Jos plateau, Nigeria, in JanuaryāFebruary 1970. A preliminary report. Am J Trop Med Hyg 19: 695ā696.
White HA, 1972. Lassa fever. A study of 23 hospital cases. Trans R Soc Trop Med Hyg 66: 390ā401.
Edington GM, White HA, 1972. The pathology of Lassa fever. Trans R Soc Trop Med Hyg 66: 381ā389.
Hastie KM, Liu T, Li S, King LB, Ngo N, Zandonatti MA, Woods VL Jr, de la Torre JC, Saphire EO, 2011. Crystal structure of the Lassa virus nucleoprotein-RNA complex reveals a gating mechanism for RNA binding. Proc Natl Acad Sci USA 108: 19365ā19370.
Grove JN, Branco LM, Boisen ML, Muncy IJ, Henderson LA, Schieffellin JS, Robinson JE, Bangura JJ, Fonnie M, Schoepp RJ, Hensley LE, Seisay A, Fair JN, Garry RF, 2011. Capacity building permitting comprehensive monitoring of a severe case of Lassa hemorrhagic fever in Sierra Leone with a positive outcome: case report. Virol J 8: 314.
Schieffelin JS, Costin JM, Nicholson CO, Orgeron NM, Fontaine KA, Isern S, Michael SF, Robinson JE, 2010. Neutralizing and non-neutralizing monoclonal antibodies against dengue virus E protein derived from a naturally infected patient. Virol J 7: 28.
Fisher-Hoch SP, McCormick JB, 2001. Towards a human Lassa fever vaccine. Rev Med Virol 11: 331ā341.
Fulhorst CF, Milazzo ML, Armstrong LR, Childs JE, Rollin PE, Khabbaz R, Peters CJ, Ksiazek TG, 2007. Hantavirus and arenavirus antibodies in persons with occupational rodent exposure. Emerg Infect Dis 13: 532ā538.
Bowen MD, Rollin PE, Ksiazek TG, Hustad HL, Bausch DG, Demby AH, Bajani MD, Peters CJ, Nichols ST, 2000. Genetic diversity among Lassa virus strains. J Virol 74: 6992ā7004.
Past two years | Past Year | Past 30 Days | |
---|---|---|---|
Abstract Views | 54 | 54 | 19 |
Full Text Views | 595 | 160 | 2 |
PDF Downloads | 231 | 60 | 1 |
Lassa fever is an acute and sometimes severe viral hemorrhagic illness endemic in West Africa. One important question regarding Lassa fever is the duration of immunoglobulin G (IgG) antibody after infection. We were able to locate three persons who worked in Nigeria dating back to the 1940s, two of whom were integrally involved in the early outbreaks and investigations of Lassa fever in the late 1960s, including the person from whom Lassa virus was first isolated. Two persons had high titers of Lassa virus-specific IgG antibody over 40 years after infection, indicating the potential for long-term duration of these antibodies. One person was likely infected in 1952, 17 years before the first recognized outbreak. We briefly recount the fascinating stories of these three pioneers and their important contribution to our understanding of Lassa fever.
Financial support: Financial support for this study came from the Tulane School of Public Health and Tropical Medicine and the National Institutes of Health.
Authors' addresses: Nell Bond, Lina M. Moses, and Andrew J. Bennett, Tulane School of Public Health and Tropical Medicine, Department of Tropical Medicine, New Orleans, LA, E-mails: nbond@tulane.edu, lmoses2@tulane.edu, and andrew.j.bennett@gmail.com. John S. Schieffelin, Tulane School of Medicine, Pediatrics Department, Section of Infectious Diseases, New Orleans, LA, E-mail: jschieff@tulane.edu. Daniel G. Bausch, Tulane School of Public Health and Tropical Medicine, Department of Tropical Medicine and Tulane School of Medicine, Internal Medicine Department, Section of Infectious Diseases, New Orleans, LA, E-mail: dbausch@tulane.edu.
Enria DA, Mills JN, Bausch D, Shieh W, Peters CJ, 2011. Arenavirus infections. Guerrant RL, Walker DH, Weller PF, eds. Tropical Infectious Diseases: Principles, Pathogens, and Practice, 3rd ed. Philadelphia, PA: Churchill Livingstone, 449ā461.
Frame JD, Baldwin JM Jr, Gocke DJ, Troup JM, 1970. Lassa fever, a new virus disease of man from West Africa. I. Clinical description and pathological findings. Am J Trop Med Hyg 19: 670ā676.
Bausch DG, Rollin PE, Demby AH, Coulibaly M, Kanu J, Conteh AS, Wagoner KD, McMullan LK, Bowen MD, Peters CJ, Ksiazek TG, 2000. Diagnosis and clinical virology of Lassa fever as evaluated by enzyme-linked immunosorbent assay, indirect fluorescent-antibody test, and virus isolation. J Clin Microbiol 38: 2670ā2677.
Wulff H, Lange JV, 1975. Indirect immunofluorescence for the diagnosis of Lassa fever infection. Bull World Health Organ 52: 429ā436.
Van der Waals FW, Pomeroy KL, Goudsmit J, Asher DM, Gajdusek DC, 1986. Hemorrhagic fever virus infections in an isolated rainforest area of central Liberia. Limitations of the indirect immunofluorescence slide test for antibody screening in Africa. Trop Geogr Med 38: 209ā214.
Fabiyi A, 1976. Lassa fever (arenaviruses) as a public health problem. Bull Pan Am Health Organ 10: 335ā337.
McCormick JB, Webb PA, Krebs JW, Johnson KM, Smith ES, 1987. A prospective study of the epidemiology and ecology of Lassa fever. J Infect Dis 155: 437ā444.
Pinneo L, Pinneo R, 1971. Mystery virus from Lassa. Am J Nurs 71: 1352ā1355.
Carey DE, Kemp GE, White HA, Pinneo L, Addy RF, Fom AL, Stroh G, Casals J, Henderson BE, 1972. Lassa fever. Epidemiological aspects of the 1970 epidemic, Jos, Nigeria. Trans R Soc Trop Med Hyg 66: 402ā408.
Frame JD, 1975. Surveillance of Lassa fever in missionaries stationed in West Africa. Bull World Health Organ 52: 593ā598.
Troup JM, White HA, Fom AL, Carey DE, 1970. An outbreak of Lassa fever on the Jos plateau, Nigeria, in JanuaryāFebruary 1970. A preliminary report. Am J Trop Med Hyg 19: 695ā696.
White HA, 1972. Lassa fever. A study of 23 hospital cases. Trans R Soc Trop Med Hyg 66: 390ā401.
Edington GM, White HA, 1972. The pathology of Lassa fever. Trans R Soc Trop Med Hyg 66: 381ā389.
Hastie KM, Liu T, Li S, King LB, Ngo N, Zandonatti MA, Woods VL Jr, de la Torre JC, Saphire EO, 2011. Crystal structure of the Lassa virus nucleoprotein-RNA complex reveals a gating mechanism for RNA binding. Proc Natl Acad Sci USA 108: 19365ā19370.
Grove JN, Branco LM, Boisen ML, Muncy IJ, Henderson LA, Schieffellin JS, Robinson JE, Bangura JJ, Fonnie M, Schoepp RJ, Hensley LE, Seisay A, Fair JN, Garry RF, 2011. Capacity building permitting comprehensive monitoring of a severe case of Lassa hemorrhagic fever in Sierra Leone with a positive outcome: case report. Virol J 8: 314.
Schieffelin JS, Costin JM, Nicholson CO, Orgeron NM, Fontaine KA, Isern S, Michael SF, Robinson JE, 2010. Neutralizing and non-neutralizing monoclonal antibodies against dengue virus E protein derived from a naturally infected patient. Virol J 7: 28.
Fisher-Hoch SP, McCormick JB, 2001. Towards a human Lassa fever vaccine. Rev Med Virol 11: 331ā341.
Fulhorst CF, Milazzo ML, Armstrong LR, Childs JE, Rollin PE, Khabbaz R, Peters CJ, Ksiazek TG, 2007. Hantavirus and arenavirus antibodies in persons with occupational rodent exposure. Emerg Infect Dis 13: 532ā538.
Bowen MD, Rollin PE, Ksiazek TG, Hustad HL, Bausch DG, Demby AH, Bajani MD, Peters CJ, Nichols ST, 2000. Genetic diversity among Lassa virus strains. J Virol 74: 6992ā7004.
Past two years | Past Year | Past 30 Days | |
---|---|---|---|
Abstract Views | 54 | 54 | 19 |
Full Text Views | 595 | 160 | 2 |
PDF Downloads | 231 | 60 | 1 |